Clinical TopicsWeb Exclusives

FDA approves new drug for chronic lymphocytic leukemia

Share

On April 11, the U.S. the Food and Drug Administration (FDA) approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia who have the chromosomal abnormality 17p deletion and who have been treated with at least one prior therapy. Read more

Test Your Knowledge

In what way does emotional intelligence affect nursing leaders in team and patient care settings?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts